RY 172.87 0.0058% TD 78.01 -1.4528% SHOP 110.31 -2.1988% CNR 156.81 1.096% ENB 56.97 -0.5933% CP 109.07 -0.8815% BMO 128.45 -0.1089% TRI 231.74 0.5641% CNQ 48.255 -1.5606% BN 74.66 -0.5859% ATD 73.98 -0.1485% CSU 4300.0 -2.1838% BNS 72.19 -0.7015% CM 86.42 0.0463% SU 53.11 -1.8481% TRP 64.595 -1.4118% NGT 80.19 -1.1708% WCN 250.57 -0.012% MFC 41.23 -0.9132% BCE 45.85 -0.4343%
Last update at 2024-10-23T18:00:05.073363Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -22.72700M | -8.47700M | -4.72300M | -6.23000M | 9.64M |
| Minority interest | - | - | - | - | - |
| Net income | -30.19800M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Selling general administrative | 8.23M | 5.92M | 4.76M | 6.62M | 8.89M |
| Selling and marketing expenses | 8.23M | 1.35M | 1.13M | 1.21M | 3.11M |
| Gross profit | 5.48M | 5.17M | 1.33M | 0.12M | 24.78M |
| Reconciled depreciation | 0.14M | 0.14M | 0.23M | 0.32M | 0.06M |
| Ebit | -15.25300M | -8.67100M | -6.06400M | -9.54400M | 9.64M |
| Ebitda | -7.64700M | -8.52600M | -7.90900M | -9.22900M | 9.70M |
| Depreciation and amortization | 7.61M | 0.14M | -1.84500M | 0.32M | 0.06M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -15.25300M | -8.67100M | -6.06400M | -9.54400M | 9.84M |
| Other operating expenses | 20.89M | 13.93M | 9.72M | 10.08M | 17.04M |
| Interest expense | 0.00300M | 0.02M | 3.42M | 0.59M | 0.00000M |
| Tax provision | 0.00000M | -0.10900M | 0.40M | -0.18800M | 5.45M |
| Interest income | 0.88M | 0.21M | 1.70M | 4.61M | 0.92M |
| Net interest income | -0.00300M | -0.02100M | -0.73600M | -0.59300M | 0.28M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 7.47M | -0.10900M | 0.40M | -0.18800M | 5.45M |
| Total revenue | 5.64M | 5.26M | 3.65M | 0.53M | 26.88M |
| Total operating expenses | 20.74M | 13.84M | 7.40M | 9.67M | 14.94M |
| Cost of revenue | 0.16M | 0.09M | 2.32M | 0.41M | 2.10M |
| Total other income expense net | -7.47400M | 0.19M | 1.34M | 3.31M | -0.20300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -22.72700M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Net income applicable to common shares | -22.72700M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 56.03M | 80.10M | 37.28M | 19.98M | 25.01M |
| Intangible assets | 0.00000M | 0.62M | 0.06M | 0.04M | 0.06M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.49M | 1.77M | 0.87M | 1.21M | 1.21M |
| Total liab | 20.25M | 27.12M | 24.07M | 22.44M | 23.10M |
| Total stockholder equity | 35.78M | 52.99M | 13.21M | -2.46300M | 1.91M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.94M | 1.89M | 3.00M | 2.93M | 2.57M |
| Common stock | 293.41M | 293.41M | 235.01M | 224.53M | 222.34M |
| Capital stock | 293.41M | 293.41M | 235.01M | 224.53M | 222.34M |
| Retained earnings | -352.08400M | -334.61900M | -322.65900M | -316.89100M | -309.78100M |
| Other liab | - | 19.32M | 19.00M | 16.53M | 17.51M |
| Good will | 0.00000M | 8.13M | 8.81M | 8.05M | 8.21M |
| Other assets | 0.32M | 0.34M | 0.34M | 0.36M | 0.42M |
| Cash | 50.61M | 65.30M | 24.27M | 7.84M | 14.51M |
| Cash and equivalents | 0.00000M | 9.70M | 0.35M | 7.84M | 14.51M |
| Total current liabilities | 7.04M | 7.77M | 5.01M | 5.66M | 5.60M |
| Current deferred revenue | 2.95M | 4.82M | 2.19M | 0.99M | 0.07M |
| Net debt | -50.43200M | -65.13900M | -24.08700M | -6.93500M | -14.51200M |
| Short term debt | 0.11M | 0.13M | 0.14M | 0.65M | 0.00000M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.18M | 0.16M | 0.18M | 0.90M | - |
| Other stockholder equity | 95.42M | 94.87M | 101.91M | 89.81M | 89.34M |
| Property plant equipment | 0.22M | 0.19M | 0.18M | 0.62M | 0.07M |
| Total current assets | 55.49M | 70.82M | 27.89M | 10.91M | 16.26M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 44.23M | 4.34M | -10.55300M | -6.36500M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.16M | 3.67M | 1.68M | 0.66M | 0.29M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.23M | 0.07M | 0.02M | 1.20M | 0.24M |
| Accounts payable | 2.04M | 0.93M | 1.19M | 1.09M | 1.28M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.96700M | -0.67800M | -1.04500M | 0.09M | 0.01M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 235.01M | 224.53M | 222.34M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.32M | 0.34M | 0.34M | 0.36M | 0.42M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.54M | 9.28M | 9.39M | 9.07M | 8.76M |
| Capital lease obligations | 0.18M | 0.16M | 0.18M | 0.90M | - |
| Long term debt total | 0.07M | 0.03M | 0.05M | 0.26M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.01200M | -0.65800M | 0.06M | 0.05M | -0.03500M |
| Change to liabilities | - | 3.64M | 3.08M | 0.13M | -0.18600M |
| Total cashflows from investing activities | -0.01200M | -0.65800M | 0.06M | 0.05M | -0.03500M |
| Net borrowings | - | -0.12700M | -0.26500M | -0.61400M | -0.61400M |
| Total cash from financing activities | -0.11800M | 51.04M | 20.47M | 3.89M | 3.89M |
| Change to operating activities | - | -1.09900M | -1.23400M | -1.04200M | -1.85300M |
| Net income | -22.72700M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Change in cash | -14.68900M | 41.03M | 16.43M | -6.67400M | 6.73M |
| Begin period cash flow | 65.30M | 24.27M | 7.84M | 14.51M | 7.78M |
| End period cash flow | 50.61M | 65.30M | 24.27M | 7.84M | 14.51M |
| Total cash from operating activities | -13.68000M | -8.58100M | -4.12900M | -10.72500M | 6.83M |
| Issuance of capital stock | 0.00000M | 34.20M | 23.50M | 4.99M | 0.00000M |
| Depreciation | 0.14M | 0.14M | 0.23M | 0.32M | 0.06M |
| Other cashflows from investing activities | -0.00100M | -0.02000M | 0.05M | 0.05M | -0.05000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.16100M | -0.05600M | 1.18M | -0.97100M | 0.31M |
| Change to account receivables | - | 0.12M | -1.33000M | -0.72900M | -0.09500M |
| Sale purchase of stock | 0.00000M | 54.29M | 23.50M | 5.30M | 0.00000M |
| Other cashflows from financing activities | 0.02M | 16.96M | -2.76700M | -0.48100M | -0.03500M |
| Change to netincome | - | -2.85800M | -2.37700M | -3.10400M | 2.73M |
| Capital expenditures | 0.01M | 0.64M | 0.03M | 0.03M | 0.00900M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.60M | 2.50M | 2.40M | -2.44400M | -0.15100M |
| Stock based compensation | 0.54M | 0.31M | 0.06M | 0.79M | 0.57M |
| Other non cash items | 7.76M | -3.16900M | -1.70600M | -3.34700M | -1.31800M |
| Free cash flow | -13.69100M | -9.22000M | -4.12900M | -10.72500M | 6.82M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AEZS Aeterna Zentaris Inc |
- -% | - | - | - | 1.86 | 0.36 | 0.20 | 1.71 |
| FRX Fennec Pharmaceuticals Inc |
-0.04 0.64% | 6.21 | - | 33.33 | 29.10 | 84.57 | 30.47 | -23.3985 |
| SVA Sernova Corp |
- -% | 0.26 | - | - | - | 7.95 | -4.4095 | |
| EPRX Eupraxia Pharmaceuticals Inc |
- -% | 3.40 | - | - | - | 8.40 | -3.9163 | |
| TH Theratechnologies Inc. |
-0.06 3.30% | 1.76 | - | 55.25 | 1.64 | 19.46 | 2.23 | -11.7353 |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
315 Sigma Drive, Summerville, SC, United States, 29486
| Name | Title | Year Born |
|---|---|---|
| Dr. Klaus Paulini Ph.D. | Pres, CEO & Exec. Director | NA |
| Dr. Nicola Ammer M.D. | Chief Medical Officer & Sr. VP of Clinical Devel. | NA |
| Dr. Matthias Gerlach | Sr. VP Manufacturing & Supply Chain | NA |
| Mr. Giuliano La Fratta | Sr. VP of Fin. & CFO | NA |
| Dr. Michael Teifel | Sr. VP of Non-Clinical Devel. & Chief Scientific Officer | NA |
| Dr. Eckhard G. Guenther Ph.D. | Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany | NA |
| Ms. Amélie Métivier | Assistant Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...